

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 3, 2025

PE anti-mouse CD279 (PD-1)

RRID:AB_313420

Type: Antibody

Proper Citation

(BioLegend Cat# 109103, RRID:AB_313420)

Antibody Information

URL: http://antibodyregistry.org/AB_313420

Proper Citation: (BioLegend Cat# 109103, RRID:AB_313420)

Target Antigen: CD279

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse CD279 (PD-1)

Description: This monoclonal targets CD279

Target Organism: mouse

Clone ID: Clone RMP1-30

Antibody ID: AB_313420

Vendor: BioLegend

Catalog Number: 109103

Alternative Catalog Numbers: 109104

Record Creation Time: 20231110T045002+0000

Record Last Update: 20241114T233320+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse CD279 (PD-1).

No alerts have been found for PE anti-mouse CD279 (PD-1).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Yang Y, et al. (2024) Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy. Cell reports. Medicine, 5(5), 101512.

Cao T, et al. (2024) Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells. Cell, 187(9), 2288.

Sprooten J, et al. (2024) Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells. Cell reports. Medicine, 5(1), 101377.

Yang Y, et al. (2024) Dietary vitamin B3 supplementation induces the antitumor immunity against liver cancer via biased GPR109A signaling in myeloid cell. Cell reports. Medicine, 5(9), 101718.

Song J, et al. (2023) PTIR1 acts as an isoform of DDX58 and promotes tumor immune resistance through activation of UCHL5. Cell reports, 42(11), 113388.

Zhang Z, et al. (2023) Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies. Cell reports. Medicine, 4(12), 101336.

Schwarz A, et al. (2023) Crosstalk between microbiome, regulatory T cells and HCA2 orchestrates the inflammatory response in a murine psoriasis model. Frontiers in immunology, 14, 1038689.

Guilbaud E, et al. (2023) Cholesterol efflux pathways hinder KRAS-driven lung tumor progenitor cell expansion. Cell stem cell, 30(6), 800.

An J, et al. (2022) AMP-activated protein kinase alpha1 promotes tumor development via FOXP3 elevation in tumor-infiltrating Treg cells. iScience, 25(1), 103570.

Uchil PD, et al. (2019) A Protective Role for the Lectin CD169/Siglec-1 against a Pathogenic Murine Retrovirus. *Cell host & microbe*, 25(1), 87.

Barrow AD, et al. (2018) Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor. *Cell*, 172(3), 534.

Zhao Y, et al. (2018) Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. *Cell reports*, 24(2), 379.

Chatterjee S, et al. (2018) CD38-NAD⁺ Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. *Cell metabolism*, 27(1), 85.